Alphatec Hlds

Alphatec Holdings, Inc. engages in the design, development, and marketing of spinal fusion technology products and solutions for the treatment of spinal disorders. It offers intra-operative information and neuromonitoring technologies, access systems, interbody implants, fixation systems, and various biologics offerings. The company was founded on March 4, 2005 and is headquartered in Carlsbad, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Alphatec (ATEC) posts robust earnings, eyes growth through innovation

Alphatec (ATEC) delivered strong financial results in Q4 2022, with revenue growth, operational improvements, and a positive outlook for 2023.
The company's focus on innovation, surgeon adoption, and profitability underscores its strategic approach to sustainable growth and market leadership.
ATEC faces challenges in margin improvement, achieving EBITDA targets, and navigating competitive consolidation in the spine space.
However, the company remains optimistic, leveraging opportunities in procedural expansion, technological innovation, and international market expansion for future success.

Alphatec (ATEC) reports stellar Q1 growth and strategic acquisitions

Alphatec (ATEC) showcased robust revenue growth, strategic acquisitions, and a focus on enhancing procedural efficiency and surgeon adoption.
While challenges exist in achieving EBITDA break-even and expanding margins, ATEC's strong performance and growth outlook present promising opportunities.
The company's emphasis on technology integration, international expansion, and increasing robotics utilization positions ATEC for future success.

Alphatec (ATEC) reports robust Q2 growth and eyes international expansion

Alphatec's Q2 performance reflects strong revenue growth, margin expansion, and market share gains driven by strategic initiatives in spine surgery. The company's focus on innovation, surgeon adoption, and geographic expansion positions it well for future growth and success in the spine market.

Alphatec (ATEC) reports robust Q3 earnings, eyes growth opportunities

Alphatec (ATEC) delivered strong financial performance in Q3 2023, driven by revenue growth, positive adjusted EBITDA, and strategic initiatives.
The company's strengths lie in its spine surgery focus, new product launches, and advancements in informatics and robotic integration.
Challenges include managing risks, balancing growth with profitability, and navigating market disruptions, while opportunities exist in expansion and technology integration.

Alphatec (ATEC) reports robust Q4 performance, eyes international expansion

Alphatec (ATEC) had a strong Q4 2023, focusing on clinical excellence and market share growth. Challenges include managing debt and sustaining momentum. Opportunities lie in international expansion and innovative product launches.

Alphatec Hlds (ATEC) reports robust Q1 performance and growth outlook

Alphatec Hlds (ATEC) delivered a strong Q1 2024 performance with significant revenue growth, surgeon adoption, and sales team confidence, underpinned by a focus on innovation and market expansion.
While facing challenges in debt management and profitability, the company's strategic outlook, financial strength, and growth drivers position it well for future success and sustained growth.
By capitalizing on opportunities in technology integration, international expansion, and market share expansion, Alphatec is poised to drive continued innovation and value creation in the spine surgery market.

Alphatec Hlds (ATEC) reports robust Q2 growth and eyes Japan expansion

Alphatec Hlds (ATEC) delivered strong financial results in Q2 2024, showcasing growth in revenue, profitability, and surgeon engagement, while focusing on innovation and clinical distinction.
The company faces challenges in achieving cash flow break-even, entering new markets like Japan, and expanding into deformity surgery, but sees opportunities in market growth and technological advancements.
Overall, Alphatec Hlds (ATEC) remains committed to advancing spine surgery through technology, attracting surgeons to advanced tools, and driving sustainable growth through strategic initiatives.

Alphatec (ATEC) excels in Q3 earnings, eyes growth opportunities

Alphatec (ATEC) reported a robust Q3 performance marked by strong revenue growth and positive adjusted EBITDA, driven by surgical and EOS revenue increases. While challenges in gross margin and cash flow breakeven exist, the company remains optimistic about long-term financial commitments and revenue growth. ATEC's strategic focus on value creation, surgeon adoption, and innovation positions it well for future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

In recent years, Alphatec Holdings has outperformed expectations on a regular basis and successfully taken share in the $8 billion U.S. spinal disorder treatment market. The company is capitalizing on M&A-related disruptions at key competitors, which has created opportunities for Alphatec to grab additional market share. Persistent cash usage has resulted in substantial debt accumulation and material dilution for common shareholders, but the company appears adequately financed to reach cash flow breakeven by 2025.

Alphatec Holdings: Taking Market Share Amid Strong Execution - Buy

CARLSBAD, Calif.--(BUSINESS WIRE)--Alphatec Holdings, Inc. (Nasdaq: ATEC), a provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, announced today preliminary revenue results for the fourth quarter and full-year ended December 31, 2023, and provided revenue guidance for full-year 2024. Preliminary, Unaudited Fourth Quarter and Full-Year 2023 Revenue Ranges   Fourth Quarter Ended December 31, 2023 Full-Year Ended December 31, 2023 Surgical Revenue $121.8M t.

ATEC Announces Record Preliminary Revenue Results for 2023 and 2024 Revenue Guidance

CARLSBAD, Calif.--(BUSINESS WIRE)--Alphatec Holdings, Inc. (Nasdaq: ATEC), a provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, announced today that management will present at the J.P. Morgan Healthcare Conference at the Westin St. Francis Hotel in San Francisco, CA, at 3:45pm PT on January 10, 2024. Both the live webcast and the presentation materials will be available on the Investor Relations Section of the Company's website. About ATEC ATEC, through.

ATEC to Present at the 2024 J.P. Morgan Healthcare Conference

Alphatec Holdings, Inc.'s focus on growth rather than improving margins raises caution for investors. Despite strong revenue growth, the company continues to experience substantial losses and slow progress on margin improvements. The recent share sales and high debt levels contribute to investor uncertainty about the company's commitment to shareholder value.

Alphatec: Still Not Having My Back

Alphatec Holdings, Inc. (NASDAQ:ATEC ) Q3 2023 Earnings Conference Call November 6, 2023 4:30 PM ET Company Participants Pat Miles - Chairman and Chief Executive Officer Todd Koning - Chief Financial Officer Conference Call Participants Brooks O'Neil - Lake Street Capital Markets Matt Blackman - Stifel Matthew O'Brien - Piper Sandler Joshua Jennings - TD Cowen Drew Ranieri - Morgan Stanley Sean Lee - H.C. Wainwright Jason Wittes - ROTH Operator Good afternoon, everyone and welcome to the webcast of ATEC's Third Quarter Financial Results.

Alphatec Holdings, Inc. (ATEC) Q3 2023 Earnings Call Transcript

CARLSBAD, Calif.--(BUSINESS WIRE)--Alphatec Holdings, Inc. (Nasdaq: ATEC), a provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, today announced financial results for the quarter ended September 30, 2023, and recent corporate highlights. Third Quarter 2023 Financial Results   Quarter Ended September 30, 2023 Total revenue $118 million GAAP gross margin 68% Non-GAAP gross margin 72% GAAP operating expenses $118 million Non-GAAP operating expenses $94 mill.

ATEC Reports Third Quarter 2023 Financial Results and Raises Full Year 2023 Adjusted EBITDA Guidance

CARLSBAD, Calif.--(BUSINESS WIRE)--Alphatec Holdings, Inc. (Nasdaq: ATEC), a provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, announced today that management will participate in the following investor events: The Stifel Healthcare Conference at the Lotte New York Palace Hotel in New York, NY, with a fireside chat at 3:00pm ET on November 14, 2023 The Jefferies London Healthcare Conference at the Waldorf Hilton in Aldwych, London, with a fireside chat.

ATEC to Participate in Upcoming Investor Conferences

CARLSBAD, Calif.--(BUSINESS WIRE)--Alphatec Holdings, Inc. (NASDAQ:ATEC), a provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, announced today that the successful close of a $150 million secondary offering on October 27, 2023, positions the Company to accelerate investment in the revenue-generating assets required to capitalize on industry disruption. “We would like to thank our existing and new shareholders for their confidence as we better position AT.

ATEC Equipped to Support Ramping Surgical Volume With Proceeds From Secondary Offering

CARLSBAD, Calif.--(BUSINESS WIRE)--Alphatec Holdings, Inc. (“ATEC”) (NASDAQ: ATEC), a provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, today announced the closing of its previously announced underwritten public offering of 14,300,000 shares of its common stock at a public offering price of $10.50 per share. Morgan Stanley, TD Cowen, Barclays and Stifel acted as joint book-running managers in the offering. ATEC received gross proceeds from the offering.

ATEC Announces Closing of Public Stock Offering

Alphatec just priced an offering of 14.3 million shares at $10.50 per share -- a more than 18% discount from yesterday's close. The offering was filed pursuant to a previously filed shelf registration statement by the company.

Why Alphatec Holdings Stock Plunged Today

CARLSBAD, Calif.--(BUSINESS WIRE)--Alphatec Holdings, Inc. (“ATEC”) (NASDAQ: ATEC), a provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, today announced the pricing of an underwritten public offering of 14,300,000 shares of its common stock at a public offering price of $10.50 per share. The offering is expected to close on October 27, 2023, subject to the satisfaction of customary closing conditions. In connection with the offering, ATEC has granted th.

ATEC Announces Pricing of Public Offering of Common Stock

CARLSBAD, Calif.--(BUSINESS WIRE)--Alphatec Holdings, Inc. (“ATEC”) (NASDAQ: ATEC), a provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, today announced that it has commenced a proposed underwritten public offering of $150 million of shares of its common stock. In connection with the proposed offering, ATEC intends to grant the underwriters a 30-day option to purchase up to an additional $22.5 million of shares of its common stock sold in the offering.

ATEC Announces Proposed Public Offering of Common Stock

CARLSBAD, Calif.--(BUSINESS WIRE)--Alphatec Holdings, Inc. (Nasdaq: ATEC), a provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, announced today that Dave Demski, former director and Chief Executive Officer of Globus Medical, has been appointed as an independent director to the Board. The Company also announced that Keith Valentine, former Chief Executive Officer of Orthofix, has been appointed Special Advisor to the Board. With over 20 years of experien.

ATEC Enhances Board with Renowned Spine Prowess

CARLSBAD, Calif.--(BUSINESS WIRE)--Alphatec Holdings, Inc. (Nasdaq: ATEC), a provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, announced today that EOS Catalyst will be introduced at the 2023 NASS Annual Meeting. EOS Catalyst builds on the already unprecedented functionality of the EOS imaging platform with automated alignment and surgical planning capabilities. “EOS is foundational to ATEC's mission to revolutionize spine surgery,” said Pat Miles, Cha.

ATEC to Preview the Informatics Sophistication of EOS Catalyst™ at NASS 2023

CARLSBAD, Calif.--(BUSINESS WIRE)--Alphatec Holdings, Inc. (Nasdaq: ATEC), a provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, announced today that the Company's commitment to advancing lateral surgery will be prominent at the 2023 NASS Annual Meeting. The Company will introduce the Calibrate LTXTM lateral expandable implant system, technology designed to better achieve alignment goals with precise lordosis control and disc height restoration. “ATEC is.

ATEC Advances Lateral Surgery With Launch of Expandable Technology

CARLSBAD, Calif.--(BUSINESS WIRE)--Alphatec Holdings, Inc. (Nasdaq: ATEC), a provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, announced today select preliminary financial results for the third quarter ended September 30, 2023, and updated full-year 2023 revenue guidance ahead of investor meetings scheduled during the 2023 North American Spine Society (NASS) Annual Meeting. Preliminary Third Quarter 2023 Revenue Ranges   Quarter Ended September 30, 202.

ATEC Announces Preliminary Third Quarter 2023 Revenue Results and Raises Full-Year Revenue Guidance

CARLSBAD, Calif.--(BUSINESS WIRE)--Alphatec Holdings, Inc. (Nasdaq: ATEC), a provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, announced today that the Company will feature technology designed to advance its comprehensive procedural solutions at the North American Spine Society (NASS) 38th Annual Meeting, which will be held at the Los Angeles Convention Center in California from October 18 to 21, 2023. “While others in our industry grapple with distrac.

ATEC Clinical Precision and Predictability on Display at NASS 2023

Alphatec Holdings' Q2 numbers were strong, posting another double-digit upside at the top line. The company's surgical segment, particularly the LTP procedure, shows promise for growth and profitability in my view. Sentiment towards Alphatec's stock is mixed, with bullish positioning in the short-term but potential downside in the long term.

Alphatec: Price Reversal Diverges From Economic Levers That Are Well In Situ (Rating Upgrade)

Alphatec Holdings, Inc. (NASDAQ:ATEC ) Q2 2023 Earnings Conference Call August 3, 2023 4:30 PM ET Company Participants Pat Miles - Chairman and CEO Todd Koning - CFO Conference Call Participants Matt Blackman - Stifel Josh Jennings - TD Cowen Andrew Ranieri - Morgan Stanley David Saxon - Needham & Co. Aaron Wukmir - Lake Street Capital Markets Sean Lee - H.C. Wainwright Operator Good afternoon, everyone.

Alphatec Holdings, Inc. (ATEC) Q2 2023 Earnings Call Transcript

CARLSBAD, Calif.--(BUSINESS WIRE)---- $ATEC--Alphatec Holdings, Inc. (Nasdaq: ATEC), a provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, today announced financial results for the quarter ended June 30, 2023, and recent corporate highlights. Second Quarter 2023 Financial Results   Quarter Ended June 30, 2023 Total revenue $117 million GAAP gross margin 55% Non-GAAP gross margin 73% GAAP operating expenses $114 million Non-GAAP operating expenses $94 million GAAP.

ATEC Reports Second Quarter 2023 Financial Results and Raises Full Year 2023 Revenue and Adjusted EBITDA Guidance

CARLSBAD, Calif.--(BUSINESS WIRE)--Alphatec Holdings, Inc. (Nasdaq: ATEC), a provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, announced today that it will report second quarter 2023 financial results on August 3, 2023, after the market close. The Company will host a live webcast that day at 1:30 p.m. PT / 4:30 p.m. ET. Webcast To access the live webcast, please visit the Investor Relations Section of ATEC's Corporate Website. Dial-in To dial into the.

ATEC to Report Second Quarter Financial Results on August 3, 2023

Medical technology company sees 20% long-term growth as it expands into new global markets. Management projects positive cash flow in 2025.

Medical Technology Stock Breaks Out, Sees 28% Revenue Growth

Alphatec (ATEC) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Alphatec (ATEC) Surges 8.8%: Is This an Indication of Further Gains?

Alphatec specializes in spinal surgery technology and equipment. The company reported a revenue gain of 54% year over year in the first quarter.

Missed Out On Intuitive Surgical's Boom? This Stock May Be a Better Buy Now

Alphatec continues to see strong growth in the spine market. Sales growth is to be applauded, but margins remain the issue, with no progress seen on this front.

News for Alphatec Hlds Stock (ATEC)